Hong Kong and the Next Generation of Cell & Gene Therapies
With Hong Kong now host to a growing volume of public and private entities specializing in cell and gene therapy development, some market insiders spy great opportunities for the city,…
In March 2024, the Advanced Therapy Product Good Manufacturing Practice Centre (ATP GMP Centre) at the Chinese University of Hong Kong’s (CUHK) Institute of Biotechnology (HKIB) became the first university-led centre within the special administrative region to receive certification for…
With Hong Kong now host to a growing volume of public and private entities specializing in cell and gene therapy development, some market insiders spy great opportunities for the city,…
As complex cutting-edge therapies come online, industry sponsors are increasingly looking to engage with patients, caregivers, and advocacy groups earlier and more broadly in the drug development process to better…
In summer 2023, Hong Kong entered the next frontier of cancer care with the launch of its first hospital-based CAR-T clinical trial. Developed entirely within city limits by a team…
Dr Carlos Prada, Director of the Edwards Family Division of Genetics and Rare Diseases at Ann & Robert H. Lurie Children’s Hospital of Chicago, discusses how earlier diagnosis, coordinated care pathways, and emerging therapeutic modalities are reshaping outcomes for children and families. From newborn screening and multidisciplinary follow-up to the realities of clinical trials and next-generation genetic therapies, Prada highlights…
Ramon Parsons, Director of the Mount Sinai Tisch Cancer Center, reflects on four decades of progress in oncology – from molecular genetics to immunotherapy and cellular therapies – and the…
Orla Cloak, CEO of Minaris, explains how the organisation. was formed by integrating Minaris Regenerative Medicine, a dedicated cell and gene therapy (CGT) CDMO, and WuXi Advanced Therapies, which brought…
The CGT field is undergoing a critical transformation from boom to thoughtful reset. While early enthusiasm brought a rush of investment and regulatory attention, the sector is now refining its…
With a record number of recent approvals representing game-changing potential for conditions like sickle cell disease, a significant number of advanced therapies making progress in the clinic, and an uptick…
In an extensive recent PharmaBoardroom conversation, EMA Head of Advanced Therapies Ana-Hidalgo-Simon highlighted some of the most important trends around advanced therapy regulation in Europe. Hidalgo-Simon touched on why moderate…
Hong Kong’s unique history as a former British governate and current special status under the ‘one country, two systems’ administrative framework, endow it with many underlying advantages as a ‘talent…
At first glance, tiny and crowded Hong Kong may not look like an obvious destination for developing next-generation gene therapies, for all its financial firepower and international complexion. Delve deeper,…
With the global market for cell and gene therapy (CGT) products set to skyrocket in the coming years, Hong Kong is looking to get in on the action with the…
See our Cookie Privacy Policy Here
